Single dose tocilizumab for COVID‐19 associated cytokine storm syndrome: Less is more.

Authors: Boone, Niels W., Moes, Dirk Jan A. R., Ramiro, Sofia, Mostard, Remy L. M., Magro‐Checa, Cesar, van Dongen, Christel M. P., Gronenschild, Michiel, van Haren, Eric, Buijs, Jacqueline, de Vries, Annick, Peeters, Ralph, Landewé, Robert B. M., Wong, Dennis R.

Source: British Journal of Clinical Pharmacology; Apr2025, Vol. 91 Issue 4, p938-946, 9p

Subject Terms: TOCILIZUMAB, COVID-19, DRUG dosage, CLINICAL trials, CYTOKINE release syndrome, PHARMACOKINETICS, METHYLPREDNISOLONE

The unsustainable bubble of disease-modifying antirheumatic drugs in rheumatology

Authors: Landewé, Robert B M ^*

Source: In The Lancet Rheumatology April 2021 3(4):e306-e312

Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis.

Authors: Deodhar, Atul, Akar, Servet, Curtis, Jeffrey R., El-Zorkany, Bassel, Magrey, Marina, Wang, Cunshan, Wu, Joseph, Makgoeng, Solomon B., Vranic, Ivana, Menon, Sujatha, Fleishaker, Dona L., Diehl, Annette M., Fallon, Lara, Yndestad, Arne, Landewé, Robert B. M.

Source: Advances in Rheumatology; 12/18/2024, Vol. 64 Issue 1, p1-15, 15p

Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.

Authors: Mease, Philip J., Merola, Joseph F., Tanaka, Yoshiya, Gossec, Laure, McInnes, Iain B., Ritchlin, Christopher T., Landewé, Robert B. M., Asahina, Akihiko, Ink, Barbara, Heinrichs, Andrea, Bajracharya, Rajan, Shende, Vishvesh, Coarse, Jason, Coates, Laura C.

Source: Rheumatology & Therapy; Oct2024, Vol. 11 Issue 5, p1363-1382, 20p

Subject Terms: TUMOR necrosis factors, ANTIRHEUMATIC agents, PSORIATIC arthritis, TREATMENT effectiveness, ADALIMUMAB, CHRONIC diseases

The effect of rituximab on patient reported outcomes in the preclinical phase of rheumatoid arthritis: 2 year data from the PRAIRI study.

Authors: Frazzei, Giulia, Cramer, Sophie H. M., Landewé, Robert B. M., Maijer, Karen I., Gerlag, Danielle M., Tak, Paul P., de Vries, Niek, van Baarsen, Lisa G. M., van Vollenhoven, Ronald F., Tas, Sander W.

Source: RMD Open; Oct2024, Vol. 10 Issue 4, p1-6, 6p

ASAS consensus definition of early axial spondyloarthritis.

Authors: Navarro-Compán, Victoria, Benavent, Diego, Capelusnik, Dafne, van der Heijde, Désirée, Landewé, Robert B. M., Poddubnyy, Denis, van Tubergen, Astrid, Baraliakos, Xenofon, Van den Bosch, Filip E., van Gaalen, Floris A., Gensler, Lianne, López-Medina, Clementina, Marzo-Ortega, Helena, Molto, Anna, Pérez-Alamino, Rodolfo, Rudwaleit, Martin, van de Sande, Marleen, Sengupta, Raj, Weber, Ulrich, Ramiro, Sofia

Source: Annals of the Rheumatic Diseases; Sep2024, Vol. 83, p1093-1099, 7p

Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry

Authors: Bergstra, Sytske Anne ^{1, *}, Branco, Jaime C ^{2, 3}, Vega-Morales, David ⁴, Salomon-Escoto, Karen ⁵, Govind, Nimmisha ⁶, Allaart, Cornelia F ¹, Landewé, Robert B M ^{7, 8}

Source: In Annals of the Rheumatic Diseases October 2018 77(10):1413-1420

Overdiagnosis and overtreatment in rheumatology: a little caution is in order

Authors: Landewé, Robert B M ^{1, 2, *}

Source: In Annals of the Rheumatic Diseases October 2018 77(10):1394-1396

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.

Authors: Ritchlin, Christopher T., Coates, Laura C., McInnes, Iain B., Mease, Philip J., Merola, Joseph F., Yoshiya Tanaka, Akihiko Asahina, Gossec, Laure, Gottlieb, Alice B., Warren, Richard B., Ink, Barbara, Bajracharya, Rajan, Shende, Vishvesh, Coarse, Jason, Landewé, Robert B. M.

Source: Annals of the Rheumatic Diseases; Nov2023, Vol. 82 Issue 11, p1404-1414, 30p

Organ involvement and assessment in sarcoidosis.

Authors: Janssen, Marlou T. H. F., Landewé, Robert B. M., Post, Marco C., Erckens, Roel J., Mostard, Rémy L. M.

Source: Current Opinion in Pulmonary Medicine; Sep2023, Vol. 29 Issue 5, p485-492, 8p

Goodbye to the term 'ankylosing spondylitis', hello 'axial spondyloarthritis': time to embrace the ASAS-defined nomenclature.

Authors: van der Heijde, Désirée, Molto, Anna, Ramiro, Sofia, Braun, Jürgen, Dougados, Maxime, van Gaalen, Floris A., Gensler, Lianne S., Inman, Robert D., Landewé, Robert B. M., Marzo-Ortega, Helena, Navarro-Compán, Victoria, Phoka, Andri, Poddubnyy, Denis, Protopopov, Mikhail, Reveille, John, Rudwaleit, Martin, Sampaio-Barros, Percival, Sepriano, Alexandre, Sieper, Joachim, den Bosch, Filip E. Van

Source: Annals of the Rheumatic Diseases; May2024, Vol. 83 Issue 5, p547-549, 3p

Controversies in rheumatology: telemedicine—friend or foe?

Authors: Dejaco, Christian^1,2 christian.dejaco@gmx.net, Landewé, Robert B M^3,4

Source: Rheumatology. Aug2023, Vol. 62 Issue 8, p2661-2664. 4p.

Subject Terms: *MEDICAL quality control, *MEDICAL consultation, *HEALTH policy, *MEDICAL triage, *PATHOGENESIS, *RHEUMATOLOGY, *DEBATE, *PHYSICAL therapy, *MEDICAL care use, *HEALTH, *INFORMATION resources, *INFORMATION retrieval, *QUALITY of life, *INFORMATION science, *PATIENT education, *PATIENT-professional relations, *COVID-19 pandemic, *TELEMEDICINE, *PSYCHOTHERAPY

Country-level socioeconomic status relates geographical latitude to the onset of RA: a worldwide cross-sectional analysis in the METEOR registry.

Authors: Bergstra, Sytske Anne, Sepriano, Alexandre, Chopra, Arvind, Lai-Ling Winchow, Vega-Morales, David, Salomon-Escoto, Karen, Matthijssen, Xanthe M. E., Landewé, Robert B. M.

Source: Annals of the Rheumatic Diseases; Aug2023, Vol. 82 Issue 8, p1018-1024, 14p

The added value of predictive biomarkers in treat-to-target strategies for rheumatoid arthritis patients: a conceptual modelling study.

Authors: Wientjes, Maike H M, Ulijn, Evy, Kievit, Wietske, Landewé, Robert B M, Meek, Inger, Broeder, Nathan den, Herwaarden, Noortje van, Bemt, Bart J F van den, Verhoef, Lise M, Broeder, Alfons A den

Source: Rheumatology; Aug2023, Vol. 62 Issue 8, p2700-2706, 7p

Subject Terms: BIOMARKERS, STRATEGIC planning, MATHEMATICAL models, COST control, MEDICAL care costs, TREATMENT effectiveness, COMPARATIVE studies, RHEUMATOID arthritis, THEORY, COST effectiveness, PREDICTIVE validity, SENSITIVITY & specificity (Statistics), PROBABILITY theory, DISEASE remission, EVALUATION

Instrument selection for the ASAS core outcome set for axial spondyloarthritis.

Authors: Navarro-Compán, Victoria, Boel, Anne, Boonen, Annelies, Mease, Philip J., Dougados, Maxime, Kiltz, Uta, Landewé, Robert B. M., Baraliakos, Xenofon, Bautista-Molano, Wilson, Chiowchanwisawakit, Praveena, Dagfinrud, Hanne, Fallon, Lara, Garrido-Cumbrera, Marco, Gensler, Lianne, ElZorkany, Bassel Kamal, Haroon, Nigil, Yu Heng Kwan, Machado, Pedro M., Maksymowych, Walter, Molto, Anna

Source: Annals of the Rheumatic Diseases; Jun2023, Vol. 82 Issue 6, p763-772, 10p

Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis.

Authors: van Ouwerkerk, Lotte, Boers, Maarten, Emery, Paul, de Jong, Pascal H. P., Landewé, Robert B. M., Lems, Willem, Smolen, Josef S., Verschueren, Patrick, Huizinga, Tom W. J., Allaart, Cornelia F., Bergstra, Sytske Anne

Source: Annals of the Rheumatic Diseases; Apr2023, Vol. 82 Issue 4, p468-475, 8p

Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study.

Authors: Landewé, Robert B. M., Poddubnyy, Denis, Rahman, Proton, Van den Bosch, Filip E., Bolce, Rebecca, Leage, Soyi Liu, Lisse, Jeffrey R., So Young Park, Gensler, Lianne

Source: Annals of the Rheumatic Diseases; Feb2023, Vol. 82 Issue 2, following p212-216, 17p

Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study.

Authors: Combe, Bernard G., Tanaka, Yoshiya, Buch, Maya H., Nash, Peter, Burmester, Gerd R., Kivitz, Alan J., Bartok, Beatrix, Pechonkina, Alena, Xia, Katrina, Emoto, Kahaku, Kano, Shungo, Hendrikx, Thijs K., Landewé, Robert B. M., Aletaha, Daniel

Source: Rheumatology & Therapy; Feb2023, Vol. 10 Issue 1, p53-70, 18p

Subject Terms: PATIENT safety, PROGNOSIS, C-reactive protein, FINCHES, RHEUMATOID arthritis

Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.

Authors: Ortolan, Augusta, Webers, Casper, Sepriano, Alexandre, Falzon, Louise, Baraliakos, Xenofon, Landewé, Robert B. M., Ramiro, Sofia, van der Heijde, Désirée, Nikiphorou, Elena

Source: Annals of the Rheumatic Diseases; Jan2023, Vol. 82 Issue 1, p142-152, 11p

Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.

Authors: Webers, Casper, Ortolan, Augusta, Sepriano, Alexandre, Falzon, Louise, Baraliakos, Xenofon, Landewé, Robert B. M., Ramiro, Sofia, van der Heijde, Désirée, Nikiphorou, Elena

Source: Annals of the Rheumatic Diseases; Jan2023, Vol. 82 Issue 1, p130-141, 12p